{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T23:29:06Z","timestamp":1773876546847,"version":"3.50.1"},"reference-count":33,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,10,20]],"date-time":"2025-10-20T00:00:00Z","timestamp":1760918400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100001316","name":"Abbott Laboratories","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001316","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100031571","name":"Libin Cardiovascular Institute, University of Calgary","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100031571","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100020973","name":"Medtronic Canada","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100020973","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008497","name":"Boston Scientific Corporation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008497","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009014","name":"Abbott Laboratories Canada","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009014","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cjcopen.ca","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["CJC Open"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1016\/j.cjco.2025.10.006","type":"journal-article","created":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T11:17:35Z","timestamp":1761650255000},"page":"206-213","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Follow-up Dosing of Guideline-Indicated Medications After Myocardial Infarction: Insights from the Acute Myocardial Infarction Quality Assurance (AMIQA) Canada Study"],"prefix":"10.1016","volume":"8","author":[{"given":"Oswald","family":"Chen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Todd A.","family":"Wilson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthew T.","family":"Bennett","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jaimie","family":"Manlucu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6344-312X","authenticated-orcid":false,"given":"Stephen B.","family":"Wilton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.cjco.2025.10.006_bib1","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1161\/01.CIR.0000134791.68010.FA","volume":"110","author":"Antman","year":"2004","journal-title":"Circulation"},{"key":"10.1016\/j.cjco.2025.10.006_bib2","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1161\/01.CIR.59.3.421","article-title":"Variables predictive of survival in patients with coronary disease. Selection by univariate and multivariate analyses from the clinical, electrocardiographic, exercise, arteriographic, and quantitative angiographic evaluations","volume":"59","author":"Hammermeister","year":"1979","journal-title":"Circulation"},{"key":"10.1016\/j.cjco.2025.10.006_bib3","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1056\/NEJM198308113090602","article-title":"Risk stratification and survival after myocardial infarction","volume":"309","year":"1983","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cjco.2025.10.006_bib4","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1161\/01.CIR.76.1.44","article-title":"Left ventricular end-systolic volume as the major determinant of survival after recovery from myocardial infarction","volume":"76","author":"White","year":"1987","journal-title":"Circulation"},{"key":"10.1016\/j.cjco.2025.10.006_bib5","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1093\/ehjcvp\/pvac064","article-title":"Initial statin dose after myocardial infarction and long-term cardiovascular outcomes","volume":"9","author":"Kyt\u00f6","year":"2022","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"key":"10.1016\/j.cjco.2025.10.006_bib6","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.118.009517","article-title":"High-intensity versus non-high-intensity statins in patients achieving low-density lipoprotein cholesterol goal after percutaneous coronary intervention","volume":"7","author":"Kim","year":"2018","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.cjco.2025.10.006_bib7","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1056\/NEJMoa040583","article-title":"Intensive versus moderate lipid lowering with statins after acute coronary syndromes","volume":"350","author":"Cannon","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cjco.2025.10.006_bib8","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1016\/j.jacc.2015.07.047","article-title":"Effect of beta-blocker dose on survival after acute myocardial infarction","volume":"66","author":"Goldberger","year":"2015","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.cjco.2025.10.006_bib9","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/j.repc.2017.06.022","article-title":"Effect of beta-blocker dose on mortality after acute coronary syndrome","volume":"37","author":"Raposeiras-Roubin","year":"2018","journal-title":"Rev Port Cardiol (Engl Ed)"},{"key":"10.1016\/j.cjco.2025.10.006_bib10","first-page":"372","article-title":"Association between \u03b2-blocker dose and cardiovascular outcomes after myocardial infarction: insights from the SWEDEHEART registry","volume":"10","author":"Mars","year":"2021","journal-title":"Eur Heart J Acute Cardiovasc Care"},{"key":"10.1016\/j.cjco.2025.10.006_bib11","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1056\/NEJMoa030207","article-title":"Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction","volume":"348","author":"Pitt","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cjco.2025.10.006_bib12","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1016\/S0140-6736(02)09895-1","article-title":"Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: the OPTIMAAL randomised trial","volume":"360","author":"Dickstein","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.cjco.2025.10.006_bib13","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2021.36830","article-title":"Variability in reassessment of left ventricular ejection fraction after myocardial infarction in the Acute Myocardial Infarction Quality Assurance Canada Study","volume":"4","author":"Wilton","year":"2021","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.cjco.2025.10.006_bib14","first-page":"531","article-title":"CCS\/CHFS heart failure guidelines update: defining a new pharmacologic standard of care for heart failure with reduced ejection fraction","volume":"37","author":"McDonald","year":"2021","journal-title":"Can J Cardiol"},{"key":"10.1016\/j.cjco.2025.10.006_bib15","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1002\/ejhf.1351","article-title":"Medication dosing for heart failure with reduced ejection fraction\u2014opportunities and challenges","volume":"21","author":"Marti","year":"2019","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.cjco.2025.10.006_bib16","doi-asserted-by":"crossref","DOI":"10.1161\/HCQ.0000000000000099","article-title":"2020 ACC\/AHA clinical performance and quality measures for adults with heart failure","volume":"13","author":"Heidenreich","year":"2020","journal-title":"Circ Cardiovasc Qual Outcomes"},{"key":"10.1016\/j.cjco.2025.10.006_bib17","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.117.006460","article-title":"Lipid testing and statin dosing after acute myocardial infarction","volume":"7","author":"Wang","year":"2018","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.cjco.2025.10.006_bib18","first-page":"214","article-title":"2018 Canadian Cardiovascular Society\/Canadian Association of Interventional Cardiology focused update of the guidelines for the use of antiplatelet therapy","volume":"34","author":"Mehta","year":"2018","journal-title":"Can J Cardiol"},{"key":"10.1016\/j.cjco.2025.10.006_bib19","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.120.019167","article-title":"Predictors of the use of mineralocorticoid receptor antagonists in patients with left ventricular dysfunction post-ST-segment-elevation myocardial infarction","volume":"10","author":"Wong","year":"2021","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.cjco.2025.10.006_bib20","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.1016\/j.jacc.2013.04.102","article-title":"Beyond medication prescription as performance measures: optimal secondary prevention medication dosing after AMI","volume":"62","author":"Arnold","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.cjco.2025.10.006_bib21","doi-asserted-by":"crossref","DOI":"10.4414\/smw.2020.20321","article-title":"Beta-blocker use and up-titration after acute ST-segment elevation myocardial infarction: a cohort study","volume":"150","author":"Bruggmann","year":"2020","journal-title":"Swiss Med Weekly"},{"key":"10.1016\/j.cjco.2025.10.006_bib22","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1001\/jama.297.2.177","article-title":"Relationship between adherence to evidence-based pharmacotherapy and long-term mortality after acute myocardial infarction","volume":"297","author":"Rasmussen","year":"2007","journal-title":"JAMA"},{"key":"10.1016\/j.cjco.2025.10.006_bib23","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1056\/NEJM199909023411001","article-title":"The effect of spironolactone on morbidity and mortality in patients with severe heart failure","volume":"341","author":"Pitt","year":"1999","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cjco.2025.10.006_bib24","doi-asserted-by":"crossref","first-page":"2312","DOI":"10.1161\/01.CIR.100.23.2312","article-title":"Comparative effects of low and high doses of the angiotensin-converting enzyme inhibitor, lisinopril, on morbidity and mortality in chronic heart failure","volume":"100","author":"Packer","year":"1999","journal-title":"Circulation"},{"key":"10.1016\/j.cjco.2025.10.006_bib25","doi-asserted-by":"crossref","first-page":"1840","DOI":"10.1016\/S0140-6736(09)61913-9","article-title":"Effects of high-dose versus low-dose losartan on clinical outcomes in patients with heart failure (HEAAL study): a randomised, double-blind trial","volume":"374","author":"Konstam","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.cjco.2025.10.006_bib26","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1054\/jcaf.2003.34","article-title":"Tolerability to \u03b2-blocker therapy among heart failure patients in clinical practice","volume":"9","author":"Butler","year":"2003","journal-title":"J Card Fail"},{"key":"10.1016\/j.cjco.2025.10.006_bib27","doi-asserted-by":"crossref","first-page":"e38","DOI":"10.1161\/ATV.0000000000000073","article-title":"Statin safety and associated adverse events: a scientific statement from the American Heart Association","volume":"39","author":"Newman","year":"2019","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.cjco.2025.10.006_bib28","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.ahj.2015.03.019","article-title":"Persistence with secondary prevention medications after acute myocardial infarction: insights from the TRANSLATE-ACS Study","volume":"170","author":"Mathews","year":"2015","journal-title":"Am Heart J"},{"key":"10.1016\/j.cjco.2025.10.006_bib29","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.118.011793","article-title":"Association between medication adherence and 1-year major cardiovascular adverse events after acute myocardial infarction in China","volume":"8","author":"Shang","year":"2019","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.cjco.2025.10.006_bib30","first-page":"138","article-title":"Improving communication with GPs post-STEMI","volume":"23","author":"Coughlan","year":"2016","journal-title":"Brit J Cardiol"},{"key":"10.1016\/j.cjco.2025.10.006_bib31","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-020-68915-1","article-title":"Medication adherence and its determinants in patients after myocardial infarction","volume":"10","author":"Pietrzykowski","year":"2020","journal-title":"Sci Rep"},{"key":"10.1016\/j.cjco.2025.10.006_bib32","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.ahj.2017.11.014","article-title":"Left ventricular ejection fraction reassessment post\u2013myocardial infarction: current clinical practice and determinants of adverse remodeling","volume":"198","author":"Chew","year":"2018","journal-title":"Am Heart J"},{"key":"10.1016\/j.cjco.2025.10.006_bib33","doi-asserted-by":"crossref","DOI":"10.3389\/fcvm.2022.1051995","article-title":"Trajectories and determinants of left ventricular ejection fraction after the first myocardial infarction in the current era of primary coronary interventions","volume":"9","author":"Wohlfahrt","year":"2022","journal-title":"Front Cardiovasc Med"}],"container-title":["CJC Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589790X25006444?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589790X25006444?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T16:02:45Z","timestamp":1773849765000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2589790X25006444"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":33,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["S2589790X25006444"],"URL":"https:\/\/doi.org\/10.1016\/j.cjco.2025.10.006","relation":{},"ISSN":["2589-790X"],"issn-type":[{"value":"2589-790X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Follow-up Dosing of Guideline-Indicated Medications After Myocardial Infarction: Insights from the Acute Myocardial Infarction Quality Assurance (AMIQA) Canada Study","name":"articletitle","label":"Article Title"},{"value":"CJC Open","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cjco.2025.10.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Inc. on behalf of the Canadian Cardiovascular Society.","name":"copyright","label":"Copyright"}]}}